A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Is an adult patient with a confirmed diagnosis of T2DM
• Has a body mass index (BMI) of ≥25 kg/m\^2 and \<39.9 kg/m\^2
• Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
• Is on a stable dose of metformin
Locations
United States
California
Clinical Trial Site
RECRUITING
Chula Vista
Contact Information
Primary
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-ALNYLAM
Backup
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-256-9526
Time Frame
Start Date: 2026-01-15
Estimated Completion Date: 2027-05-28
Participants
Target number of participants: 40
Treatments
Experimental: ALN-4324
Participants will be administered a single dose of ALN-4324.
Placebo_comparator: Placebo
Participants will be administered a single dose of placebo.
Related Therapeutic Areas
Sponsors
Leads: Alnylam Pharmaceuticals